Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Can we Transfuse Blood Over Shorter Period?
NCT03444610Phase 1Withdrawn
- Sponsor
- King Faisal Specialist Hospital and Research Centre
- Start
- May 2018
- Primary completion
- Feb 2019
- Modality
- Recombinant Proteins and Enzymes, Cell Therapies
01
Overview
Phase 1, open-label trial of red blood cells in beta thalassemia major, thalassemia intermedia (TI), sickle cell anemia (SCA) and 2 more, sponsored by King Faisal Specialist Hospital and Research Centre. Primary endpoints: Maximum Tolerated Rate at 1 year and Dose Limiting Toxicity at 24 hours. Planned start May 2018; status: withdrawn.
02
Drugs
red blood cells
03
Conditions
beta thalassemia majorthalassemia intermedia (TI)sickle cell anemia (SCA)aplastic anemiacancer
Beyond the preview
Go deeper on NCT03444610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03444610.